Clinical Trials Browser

Recruiting × disitamab vedotin × 30 days × Clear all

NCT04879329 2026-04-21

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Phase 2 Recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06966453 2026-04-21

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms